Lipidica

Lipidica, a.s. develops the LDPC (Lipidomics Diagnostic of Pancreatic Cancer) test, a laboratory analysis of lipids in a standard blood sample for early detection of pancreatic tumours. The company runs a clinical study to verify the test's clinical function and aims to bring it into routine clinical practice.

The method builds on lipidomics research led by prof. Michal Holčapek, whose team has worked on lipid analysis for over 20 years, combined with mathematical modelling and AI algorithms. Lipidica was formed through a contract between the University of Pardubice and FONS JK Group, a.s. The laboratory operates under ČSN EN ISO 15189 and holds accreditation from the Czech Institute for Accreditation (ČIA), and the company holds an EN ISO 13485:2016 certificate for medical devices. The website does not describe specific customer segments or the revenue model.

Lipidica was founded in 2022 and is headquartered in Pardubice, Czech Republic. Its stated plans include extending the method to other cancer types and realising a national early-detection screening programme. The website lists a management board, a scientific advisory board and a team that includes quality, medical affairs and laboratory staff.

Product: LDPC lipidomic blood test for early detection of pancreatic cancer, performed in an ISO 15189 accredited laboratory.